Women with a certain type of cancer that is difficult to treat have shown promising results in the second phase of a new trial.

It’s being led by Professor Susan Banerjee, a consultant at the Royal Marsden.

Almost a third of women with low grade serious ovarian cancer saw their tumours shrink or stop growing after treatment.

The new combination of drugs tested meant toxicities were much lower leading to fewer side effects for patients.